AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening
Key facts
- Who runs it
- Ziekenhuis Oost-Limburg
- Where
- Belgium4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 10 people enrolled
- Started
- 24 Oct 2025
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional
- Treatments tested
- AI software
- Record updated
- 12 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- the subject of the NECT scan must be an adult patient (Age ≥ 18 years old)
- the NECT scan must be a NECT scan from the brain
- the NECT scan must contain the entire brain
- the patient should have at least one of the following risk factors for developing a brain aneurysm; patient is female; patient has a family history of brain aneurysms; patient is 40 years or older; patient has or is treated for a high blood pressure; patient actively smokes cigarettes at time of inclusion
- a first informed consent form must be signed before brain NECT scans can be transferred to Robovision
- a second signed written informed consent must be obtained before follow-up data will be gathered, if applicable
Who cannot take part
- There are no specific exclusion criteria
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to verify the opportunistic screening potential of the AI software for detection of brain unruptured intracranial aneurysms (UIA) on routinely performed brain NECT scans in a prospective setting in the Belgian population.
Read full original descriptionShow less
The main question the study aims to answer is: Does the AI algorithm has potential to be used as clinical screening potential for detection of brain UIA on brain NECT scans?
The performance and the clinical use of the AI algorithm will be measured based on the number of UIA detected by the AI software compared to the number of UIA confirmed by review of a radiologist compared to the number of UIA already known by review of the electronic patient file/additional diagnostic research.
Participants will be followed-up following Standard-of-Care (SoC). In addition, participants will be requested to complete a questionnaire (the EQ-5D-5L questionnaire).
Furthermore, patient outcomes, complications/death related to the possible (un)ruptured brain aneurysm will be assessed 5 years after study enrolment.
The group in the trial
- Brain NECT scans with possible UIA detected by AI software and radiologistOther group
Patients that have had a brain NECT scans on which the AI software detected a possible unruptured intracranial brain aneurysm (UIA) and which the radologist confirmed as possible UIA can participate in the study (= enrolled subjects). They are requested to sign Informed Consent Form (ICF) after which follow-up data regarding the untruptured intracranial aneurysm (UIA) will be gathered.
Treatment: AI software
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 12 January 2026